![Boston Scientific](http://media.vumedi.com/thumbs/channel_logo/2017/6/0de96395-398c-4cb9-8099-e871a5e9dd16.png.200x0_q85.png)
Boston Scientific
Cost-Effectiveness Analysis of TARE utilizing TheraSphere Y-90 Glass Microspheres vs. cTACE & DEB-TACE
Listen to Interventional Radiologists, Dr. Ahmed and Dr. Patel discuss their latest cost-effectiveness analysis for TARE utilizing TheraSphere vs. cTACE and DEB-TACE. This analysis was driven by an unmet need to understand the economics of TARE vs. cTACE & DEB-TACE in the US.
The analysis demonstrates that TARE is cost-effective vs. cTACE and provides more quality-adjusted lifer years than DEB-TACE, demonstrating that TARE procedures utilizing TheraSphere offer cost savings over time and improved long-term outcomes.
The analysis demonstrates that TARE is cost-effective vs. cTACE and provides more quality-adjusted lifer years than DEB-TACE, demonstrating that TARE procedures utilizing TheraSphere offer cost savings over time and improved long-term outcomes.
Login to view comments.
Click here to Login
Interventional Oncology